Hepion Pharmaceuticals
Business Services · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5 Madison Ave Ste 400, Morristown, New J...Phone Number
(416) 699-5273Website
www.hepionpharma.comRevenue
-Stock Symbol
HEPAIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Hepion Pharmaceuticals
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. The Companys lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models and is currently in Phase 2 clinical development for the treatment of NASH.Explore more
Hepion Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hepion Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Hepion Pharmaceuticals launches new products
Check out if Hepion Pharmaceuticals is spiking on competitors!
Click to see if Hepion Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Hepion Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Check if Hepion Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Hepion Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Hepion Pharmaceuticals
Hepion Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Hepion Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Hepion Pharmaceuticals
Compare insights from companies similar to Hepion Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hepion Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hepion Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hepion Pharmaceuticals.
Hepion Pharmaceuticals financials insights
Gather financial insights about Hepion Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2026
Private Equity
$700K
Hepion Pharmaceuticals Tech Stack
A closer look at the technologies used by Hepion Pharmaceuticals
Most Recent Scoops
Funding
Funding
Promotion
Executive Move
Kaouthar Lbiati has recently been promoted from Interim Chief Executive Officer to the role of Chief Executive Officer.
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Hepion Pharmaceuticals News & Media
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB VHepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that Dr. Kaouthar Lbiati has been named as interim Chief Executive Officer, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is reHepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the CompanyBiotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Hepion Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on Artificial Intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. The Companys lead drug candidate, rencofilstat, is a... Read More
